C. Lance Cowey

21.8k total citations · 1 hit paper
72 papers, 2.7k citations indexed

About

C. Lance Cowey is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C. Lance Cowey has authored 72 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 46 papers in Molecular Biology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C. Lance Cowey's work include Cancer Immunotherapy and Biomarkers (32 papers), CAR-T cell therapy research (30 papers) and Melanoma and MAPK Pathways (30 papers). C. Lance Cowey is often cited by papers focused on Cancer Immunotherapy and Biomarkers (32 papers), CAR-T cell therapy research (30 papers) and Melanoma and MAPK Pathways (30 papers). C. Lance Cowey collaborates with scholars based in United States, Italy and United Kingdom. C. Lance Cowey's co-authors include James Larkin, Vanna Chiarion‐Sileni, Christopher D. Lao, F. Stephen Hodi, Jedd D. Wolchok, Piotr Rutkowski, Dirk Schadendorf, René González, Jean-Jacques Grob and Iván Márquez‐Rodas and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

C. Lance Cowey

66 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

2018 1.0k citations F. Stephen Hodi, Vanna Chiarion‐Sileni et al. The Lancet Oncology profile →

Peers

C. Lance Cowey

ONCOL

IMMUN

PRM

David Gyorki Australia

Wen‐Jen Hwu United States

Chuanliang Cui China

Shijun Kang China

Zeynep Eroglu United States

Antonio Maria Grimaldi Italy

Elisa A. Rozeman Netherlands

Theresa M. Salay United States

Ariel López-Chávez United States

Nikhil I. Khushalani United States

David Gyorki Australia

C. Lance Cowey

2.1k ×1.1

ONCOL

1.2k ×1.2

577 ×0.8

IMMUN

459 ×0.7

PRM

532 ×1.8

Citations per year, relative to C. Lance Cowey C. Lance Cowey (= 1×) peers David Gyorki

Countries citing papers authored by C. Lance Cowey

Since Specialization

Citations

This map shows the geographic impact of C. Lance Cowey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Lance Cowey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Lance Cowey more than expected).

Fields of papers citing papers by C. Lance Cowey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Lance Cowey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Lance Cowey. The network helps show where C. Lance Cowey may publish in the future.

Co-authorship network of co-authors of C. Lance Cowey

This figure shows the co-authorship network connecting the top 25 collaborators of C. Lance Cowey. A scholar is included among the top collaborators of C. Lance Cowey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Lance Cowey. C. Lance Cowey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ascierto, Paolo A., Michele Del Vecchio, Barbara Merelli, et al.. (2025). 1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma. Annals of Oncology. 36. S887–S888.

Larkin, John O., Piotr Rutkowski, Christopher D. Lao, et al.. (2024). LBA43 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma. Annals of Oncology. 35. S1234–S1235. 2 indexed citations

Zakharia, Yousef, Sylvia Lee, Robert M. Jotte, et al.. (2024). Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with previously treated metastatic non-small cell lung cancer (NSCLC) or cutaneous melanoma (SGN35-033): Overall survival.. Journal of Clinical Oncology. 42(16_suppl). 2617–2617. 1 indexed citations

Hodi, F. Stephen, Vanna Chiarion‐Sileni, René González, et al.. (2023). Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.. Journal of Clinical Oncology. 41(16_suppl). 9542–9542.

Weber, Jeffrey S., Adnan Khattak, Matteo S. Carlino, et al.. (2023). LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response. Annals of Oncology. 34. S1288–S1289. 5 indexed citations

Ascierto, Paolo A., Michele Del Vecchio, Barbara Merelli, et al.. (2023). 1089P Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238. Annals of Oncology. 34. S656–S656. 4 indexed citations

Cowey, C. Lance, et al.. (2021). 1029TiP Phase II trial of pembrolizumab (pembro) and brentuximab vedotin (BV) in patients with metastatic solid malignancies after progression on prior programmed cell death protein (PD)-1 inhibitors (SGN35-033). Annals of Oncology. 32. S862–S862. 1 indexed citations

Cowey, C. Lance, et al.. (2020). 1116P Real-world clinical outcomes with pembrolizumab (pembro) for treatment of advanced melanoma: Evidence from the United States community oncology setting. Annals of Oncology. 31. S752–S752.

Adjei, Alex A., Muhammad S. Beg, Jason M. Melear, et al.. (2020). 536MO A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours. Annals of Oncology. 31. S469–S469. 1 indexed citations

10.

Weber, Jeffrey S., Michele Del Vecchio, Mario Mandalà, et al.. (2020). 1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238. Annals of Oncology. 31. S731–S732. 6 indexed citations

11.

Hodi, F. Stephen, Vanna Chiarion‐Sileni, René González, et al.. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. The Lancet Oncology. 19(11). 1480–1492. 1009 indexed citations breakdown →

12.

Wolchok, Jedd D., Vanna Chiarion‐Sileni, René González, et al.. (2015). Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).. Journal of Clinical Oncology. 33(15_suppl). LBA1–LBA1. 7 indexed citations

13.

Arreola, Alexandra, C. Lance Cowey, Jonathan L. Coloff, Jeffrey C. Rathmell, & W. Kimryn Rathmell. (2014). HIF1α and HIF2α Exert Distinct Nutrient Preferences in Renal Cells. PLoS ONE. 9(5). e98705–e98705. 13 indexed citations

14.

Cowey, C. Lance. (2013). Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond. Dermatology and Therapy. 3(1). 17–31. 16 indexed citations

15.

Sonpavde, Guru, C. Lance Cowey, Beth A. Hellerstedt, et al.. (2012). Administration of Cisplatin-Based Chemotherapy for Advanced Urothelial Carcinoma in the Community. Clinical Genitourinary Cancer. 10(1). 1–5. 43 indexed citations

16.

Josephs, Debra H., Thomas E. Hutson, C. Lance Cowey, et al.. (2011). Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. British Journal of Urology. 108(8). 1279–1283. 44 indexed citations

17.

Hutson, Thomas E., Ronald M. Bukowski, C. Lance Cowey, et al.. (2010). Sequential use of targeted agents in the treatment of renal cell carcinoma. Critical Reviews in Oncology/Hematology. 77(1). 48–62. 46 indexed citations

18.

Cowey, C. Lance, Julia R. Fielding, & W. Kimryn Rathmell. (2009). The Loss of Radiographic Enhancement in Primary Renal Cell Carcinoma Tumors Following Multitargeted Receptor Tyrosine Kinase Therapy is an Additional Indicator of Response. Urology. 75(5). 1108–1113.e1. 22 indexed citations

19.

García, Jorge A., C. Lance Cowey, & Paul A. Godley. (2009). Renal cell carcinoma. Current Opinion in Oncology. 21(3). 266–271. 27 indexed citations

20.

Hickey, Michele M., et al.. (2009). VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Oncogene. 28(14). 1694–1705. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact